TVGN trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TVGN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Tevogen Bio Holdings Inc. (TVGN) has a Wall Street consensus price target of N/A, based on estimates from 1 covering analysts. The company has a market capitalization of $1.94B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Hold, with 0 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, TVGN trades at a trailing P/E of -104.9x. Analysts expect EPS to grow -6342.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
IMVTImmunovant, Inc. | $7.8B | $38.10 | $45.00 | +27.3% | Buy | — | 23 |
RCKTRocket Pharmaceuticals, Inc. | $378M | $3.46 | $5.00 | +49.3% | Buy | — | 19 |
FATEFate Therapeutics, Inc. | $251M | $2.15 | $5.50 | +163.2% | Buy | — | 31 |
TGTXTG Therapeutics, Inc. | $8.3B | $54.40 | $54.50 | +2.4% | Buy | 38.6x | 13 |
ADMAADMA Biologics, Inc. | $2.0B | $8.57 | $21.00 | +152.7% | Buy | 10.0x | 10 |
NVAXNovavax, Inc. | $1.5B | $9.00 | $18.00 | +97.2% | Buy | — | 23 |
DYAIDyadic International, Inc. | $29M | $0.78 | — | — | — | — | — |
VXRTVaxart, Inc. | $128M | $0.53 | $2.00 | +263.0% | Buy | — | 3 |
OCGNOcugen, Inc. | $437M | $1.29 | $5.00 | +303.2% | Buy | — | 6 |
CRLCharles River Laboratories International, Inc. | $8.7B | $181.56 | $214.14 | +15.8% | Buy | 16.7x | 37 |
Quick answers to the most common questions about buying TVGN stock.
The consensus price target for TVGN is $N/A, close to the current price of $9.82 (N/A% implied move). Based on 1 analyst estimates, the stock appears fairly valued near current levels.
TVGN has a consensus rating of "Hold" based on 1 Wall Street analysts. The rating breakdown is mixed, with 1 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
TVGN's current price is $9.82 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for TVGN, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
TVGN is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TVGN stock forecast based on 1 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Hold".
TVGN appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TVGN analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.